Advertisement
U.S. markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
79.80+0.63 (+0.80%)
At close: 04:00PM EDT
79.96 +0.16 (+0.20%)
After hours: 06:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Outside Bar (Bearish)

Outside Bar (Bearish)

Previous Close79.17
Open79.62
Bid79.62 x 200
Ask79.85 x 200
Day's Range77.08 - 79.98
52 Week Range55.02 - 98.40
Volume487,583
Avg. Volume771,159
Market Cap3.78B
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-5.27
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est123.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AXSM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Axsome Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermWas that a case of quarter-end buying by institutions? Over the last 50 minutes of the trading session on Wednesday, the S&P 500 (SPX) took off like a rocket, surging 30 points and finishing 0.9% higher on the day and at another all-time high. But the biggest winners on the day were small-caps, with the Russell 2000 (IWM) surging 2.2% and the S&P 600 (SML) spiking 2.4%. The IWM is breaking out of a more-than two-year base and closed at its highest level since December 2021.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • Insider Monkey

    30 Countries with the Lowest Depression Rates

    In this article, we will be taking a look at the 30 countries with the lowest depression rates. If you do not want to learn about the global depression treatment market, head straight to the 5 Countries with the Lowest Depression Rates. In countries with the lowest depression rates, individuals experience lower prevalence rates of […]

  • Insider Monkey

    20 Cloudiest Cities in the U.S., Ranked

    In this article, we will take a look at the top 20 cloudiest cities in the U.S., Ranked. If you would like to skip our discussion on the diverse weather patterns across the country, you can go to the 5 Cloudiest Cities in the U.S., Ranked. Ranking fourth in terms of land area globally, the […]

  • GlobeNewswire

    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients

    77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectiv